Recent News

• 02.12.2026 - INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
• 02.10.2026 - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
• 01.27.2026 - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

Recent Filings

• 01.27.2026 - EX-99.1 EX-99.1
• 01.27.2026 - 8-K Current report
• 12.23.2025 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 12.19.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.10.2025 - 8-K Current report
• 12.08.2025 - 8-K Current report
• 12.08.2025 - 8-A12B/A Registration of securities [Section 12(b)]
• 12.05.2025 - 8-K Current report
• 12.05.2025 - EX-99.1 EX-99.1